



Our Facility

A **1,450 sqm** manufacturing facility comprising of:

- 14 GMP-compliant Clean Suites
- 4 Translational Laboratories
- 1 Quality Control Laboratory



Our Operating Model

PRODUCT TYPES*

**Variety of Product Types,
High-mix, Low Volume**

- Chimeric Antigen Receptor (CAR) T cells
- Natural Killer (NK) cells
- Induced Pluripotent Stem cells (iPSCs) and Mesenchymal Stem cells (MSCs)
- Allogeneic Therapeutics
- Dendritic cells
- Cytokine Induced Killer (CIK) cells




CAPABILITIES

Our Service Provision

-  Phase Appropriate - Good Manufacturing Practices
-  Process/Assay Development
-  Process Validation/ Clinical Manufacturing
-  Product Characterisation
-  Regulatory Support
-  Manpower & Training

OUTCOMES

Supporting Ecosystem Needs

-  Patients' Access
-  Research Translation
-  Product Commercialisation

* Information listed are non-exhaustive.

Connect with us
on LinkedIn!



ACTRIS



Why Partner with Us

- **Integrated End-to-End Manufacturing Support**
A centralised facility providing seamless support across the full value chain delivered by an experienced, multidisciplinary team.
- **Phase-Appropriate GMP**
An established and certified quality management system supporting investigational and specially authorised products, aligned with Singapore's regulatory frameworks.
- **Capital-Efficient Access to Specialised Infrastructure**
Immediate access to a fully operational, state-of-the-art facility – minimising upfront investment and accelerating programme initiation for clients.
- **Leverage on Established Network**
Direct access to a curated network of qualified suppliers, service providers, and analytical capabilities to support robust manufacturing & product characterisation.
- **Bridge to Regional Scale-Up & Commercialisation**
Based in Singapore, ACTRIS enables clients to leverage the country's strong R&D, regulatory, clinical, and reimbursement frameworks to advance programmes towards regional manufacturing and commercialisation.

About Us

ACTRIS was established in April 2020 to meet the increasing clinical demand for cellular therapeutics to treat various life-threatening diseases.

Our vision is to be the national and regional Centre of Excellence for facilitating discovery, process development, and manufacturing of cellular-based therapeutics across the broad spectrum of immunotherapy and regenerative medicine, encompassing both investigational and clinical-use products.

Through its specialised infrastructure and skilled workforce, ACTRIS aims to promote and support the entire value chain of the cell therapy ecosystem by enabling translational research and development, manufacturing, clinical service provision, and commercialisation across the healthcare, academic and industrial sectors.

In addition, ACTRIS will also provide value-added services such as workforce training, regulatory support, and the standardisation of ancillary materials and product testing pertaining to the delivery of cellular therapy to patients.

ACTRIS is a programme of the Consortium for Clinical Research and Innovation, Singapore (CRIS) and supported by the Singapore Ministry of Health for its set-up and through the National Medical Research Council Office, MOH Holdings Pte Ltd under the NMRC RIE2025 ACTRIS Funding Initiative (MOH-001528).

Contact Us

Advanced Cell Therapy and Research Institute, Singapore

Headquarters



23 Rochester Park, #06-01,
Singapore 139234

Facility



30 Hospital Boulevard, #19-02,
Singapore 168583



business@actris.cris.sg